ClinicalTrials.gg
Active, not recruitingNCT05739136Updated Aug 1, 2025

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

An observational study in Pregnancy Related, Pregnancy Complications and Pregnancy, High Risk, sponsored by Sumitomo Pharma Switzerland GmbH. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Sumitomo Pharma Switzerland GmbH (part of Sumitomo Pharma Co., Ltd.) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
530
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.

Planned enrollment
26th of 61
530 · median 477
Started
2025
with 16 others
Observational
61 of 127
20 open now
Primary completion
2027-05
later than 21 of 46 live
Registered
84th of 127
by date

Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 26th largest by planned enrollment of the 61 observational ones that give a count, is one of 17 that started in 2025, is one of 61 observational ones, reaches primary completion later than 21 of the 46 other live ones, and was the 84th registered.

Pregnancy Complications

411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.

Browse Pregnancy Complications studies →

Open to participants now

39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Pregnancy Complications with a site in United States, or all of them as a file.
02

Study summary

This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs). The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.

Read the detailed description

The study will identify pregnant women exposed to relugolix combination therapy during pregnancy from a United States (US) administrative claims database. The primary outcome measure is major congenital malformations (MCMs) among linked live births. Secondary outcome measures include spontaneous abortion (SAB), stillbirth, small size for gestational age (SGA), and preterm birth. Infants of pregnancies with linked live birth outcomes will be followed up to 12 months of age for identification of MCMs. Anticipated enrollment is 530 live births.

03

Conditions studied

  • Pregnancy Related
  • Pregnancy Complications
  • Pregnancy, High Risk

Keywords

  • Relugolix
  • Uterine Fibroids
  • Endometriosis
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include 2 cohorts: The exposed cohort will include pregnant women with conditions for which relugolix combination therapy is prescribed and who are exposed to relugolix combination therapy at any time during pregnancy. The unexposed cohort will include pregnant women with conditions for which relugolix combination therapy could be prescribed and who are not exposed to relugolix combination therapy at any time during pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman ≥ 18 and ≤ 50 years of age at time of conception
  • Diagnosis of a condition for which relugolix combination therapy is prescribed (diagnosis captured at any time prior to the estimated date of conception)

Cohort 1

  • Exposure to relugolix combination therapy at any time during pregnancy

Cohort 2

  • No exposure to relugolix combination therapy at any time after the estimated date of conception (during pregnancy)

Exclusion criteria

Exclusion Criteria:

  • Exposure to known teratogens during pregnancy
  • \< 6 months of continuous healthcare coverage immediately prior to date of conception
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
530 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposed Cohort

    Pregnant women with conditions for which relugolix combination therapy is prescribed, who are exposed to relugolix combination therapy at any time during pregnancy

    Drug: Relugolix + Estradiol + Norethindrone Acetate

  • Unexposed Cohort

    Pregnant women with conditions for which relugolix combination therapy could be prescribed, who are not exposed to relugolix combination therapy at any time during pregnancy

Interventions

  • DrugRelugolix + Estradiol + Norethindrone Acetate

    Drug pages: Relugolix · Estradiol · Norethindrone Acetate

    Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)

    Also known as: MVT-601, MVT-601A, MYFEMBREE

06

What researchers measure

Primary outcomes

  1. Major Congenital Malformation (MCM)

    Comparison of rate of MCM between cohorts

    Time frame: Up to 5 years

Secondary outcomes

  1. Spontaneous abortion (SAB)

    Comparison of rate of SABs between cohorts

    Time frame: Up to 5 years

  2. Stillbirth

    Comparison of rate of stillbirths between cohorts

    Time frame: Up to 5 years

  3. Preterm birth

    Comparison of rate of preterm births between cohorts

    Time frame: Up to 5 years

  4. Small for gestational age (SGA)

    Comparison of rate of SGA between cohorts

    Time frame: Up to 5 years

07

Study locations

1 site
  • SMPA
    Marlborough, Massachusetts 01752, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Feb 22, 2023
StartActual
Apr 30, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05739136
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Apr 30, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion